Articles sur le même thème :
Synthelis Biotech has been selected under the “Innovations in Biotherapies and Bioproduction” call for projects of the France 2030 program, operated by Bpifrance. This support will enable the development of Cell-Free’Up, a strategic project aimed at optimizing and industrializing our acellular bioproduction (cell-free) technology for the production of therapeutic and vaccine proteins.
The objective is to deliver a robust, reproducible, and GMP-compatible process capable of producing complex proteins at large scale, faster than traditional bioproduction systems.
To support this scale-up, Synthelis Biotech is partnering with TIBH, an industrial integrator recognized for its expertise in bioprocess development and scale-up. This complementary French consortium will accelerate access to a new generation of bioproduction solutions.
With Cell-Free’Up, Synthelis Biotech reaffirms its mission: accelerating biology to enable the production of proteins that are difficult to obtain, at a pace aligned with the needs of modern biomedicine.
Biology at speed.